TeamDrive
RUS

Chinese company invested into new Russian drug clinical trials in the USA

10 September 2018

GMP News

The Hong Kong-based pharmaceutical company Essex Bio-Investments invested $17 million into continuation of clinical trials in the United States for innovative Russian eye drops developed by Mitotech, a portfolio company of Rusnano.

“The biotechnology company Mitotech S.A. specializing in development of new pharmaceuticals based on mitochondria-targeted antioxidants – Skulachev Ions, made an agreement with Essex Bio-Investments on joint development of the Mitotech drug. According to terms of the agreement, Essex Bio-Investment will support funding of the clinical trials program in the US for SkQ1 compound developed by Mitotech. About $17 mln will be allocated for the third phase of studies, which will start already in fall 2018,” said Rusnano.

Mitotech S. A. has successfully completed the second phase of SkQ1-based eye drops in the US with participation of patients having the dry eye syndrome. This drug is known in Russia as Vizomitin.

“We expect that funding of clinical trials by a discipline independent player will make it possible to speed up the process of SkQ1 substance registration and that the unique drug will become available for patients in the United States also,” commented Olga Shpichko, Managing Director of Rusnano Management Company.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more